Onderneming RXi Pharmaceuticals Corp OTC Bulletin Board
Aandelen
US74979C1053
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
|
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19-06-12 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-17 |
Linda M. Mahoney
PRN | Corporate Officer/Principal | - | 10-11-22 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19-06-12 |
Director/Board Member | 73 | 02-05-22 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 18-04-13 |
Jonathan Freeman
BRD | Director/Board Member | 56 | 07-06-17 |
Robert Ferrara
BRD | Director/Board Member | 73 | 01-10-19 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 510 189 | 506 959 ( 99,37 %) | 0 | 99,37 % |
Bedrijfsgegevens
Phio Pharmaceuticals Corp.
11 Apex Drive Suite 300A PMB 2006
01752, Marlborough
+508-767-3861
http://www.phiopharma.com![Adres RXi Pharmaceuticals Corp](https://cdn.zonebourse.com/static/address/10879186.png)
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 46,56 mld. | |
+45,38% | 41,67 mld. | |
+0,69% | 41,16 mld. | |
+30,52% | 32,4 mld. | |
+22,30% | 28,18 mld. | |
-6,35% | 28,1 mld. | |
+49,25% | 14,52 mld. | |
+49,18% | 13,74 mld. | |
+3,45% | 12,17 mld. |
- Beurs
- Aandelen
- Koers PHIO
- Koers
- Onderneming RXi Pharmaceuticals Corp